Clostridium difficile is a leading cause of hospital-acquired illness in developed countries. Treating C. difficile infection (CDI) is complicated by antibiotic resistance, recurrence and hypervirulence of emerging strains that produce a highly toxic variant of TcdB. TcdB is a major C. difficile virulence factor that contributes to gastrointestinal damage. Our work has focused on characterizing the differences between the TcdB1 (low toxicity) and TcdB2 (high toxicity) forms of TcdB. TcdB2 enters cells more rapidly and with a higher efficiency than TcdB1 and this correlates with differences in cytotoxicity. We recently found that the 1769-1787 region of TcdB2 differs from TcdB1 at 6 residues and a peptide from this region can facilitate uptake of TcdB and other proteins. TcdB2 exhibits many of the characteristics of cell penetrating peptides (CPP) and this activity is likely to account fo the toxin's more rapid cell entry compared to TcdB1. This is the first example of a CPP derived from an intracellular bacterial toxin and may represent an entirely new area of study. As such these studies will address two specific aims. SA1: Determine the Basic Characteristics of TcdB2's Mechanism of Action and SA2: Characterize the Role of TcdB in TcdB Variability. In the first specific aim, we will assess the basic characteristic of TcdB2 and determine which residues are critical to the CPP activity of this sequence. In parallel experiments we will determine how TcdB promotes cell entry of a variety of proteins. Experiments in aim 2 will determine how variation in the 1769-1787 sequence contributes to the overall differences in toxicity between TcdB1 and TcdB2.

Public Health Relevance

Clostridium difficile infection (CDI) is a major human health problem and difficult to treat. Our studies seek to determine how TcdB and its variant forms damage host cells. The proposed work will provide insight into the mechanism through which TcdB enters cells and help understand the role of TcdB variants in CDI.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Exploratory/Developmental Grants (R21)
Project #
7R21AI121925-02
Application #
9199203
Study Section
Special Emphasis Panel (ZRG1)
Program Officer
Ranallo, Ryan
Project Start
2016-01-01
Project End
2017-12-31
Budget Start
2017-01-01
Budget End
2017-12-31
Support Year
2
Fiscal Year
2017
Total Cost
Indirect Cost
Name
University of Oklahoma Health Sciences Center
Department
Microbiology/Immun/Virology
Type
Schools of Medicine
DUNS #
878648294
City
Oklahoma City
State
OK
Country
United States
Zip Code
73104